Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Adding venetoclax to a pediatric-inspired chemo regimen significantly improved survival in adolescents and adults with newly diagnosed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). A phase 2 trial of 167 patients showed a 2-year overall survival of 78.5% — well above the 58.1% seen with chemo alone. The regimen carries notable toxicity, but researchers see particular promise for T-cell ALL.
A phase 2 trial has found that adding venetoclax to a pediatric-inspired chemotherapy regimen significantly boosts survival in adolescents and adults (ages 14–60) with newly diagnosed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The single-center study enrolled 167 patients and followed them for a median of 19.3 months, with results showing clear advantages over historical chemotherapy-only outcomes.
The venetoclax-based regimen achieved a complete response (CR) rate of 91% after first induction, and 73% of CR patients tested negative for minimal residual disease — a key marker of treatment depth. Compared to a propensity score-matched historical cohort, both overall and disease-free survival were significantly better with the new approach.
By the Numbers:
Why it matters: While the regimen is still intensive and carries real toxicity risks, it marks a meaningful step forward for a disease with historically poor outcomes in adults. Researchers are now planning a multicenter randomized trial focused on T-cell ALL, where venetoclax may offer the greatest untapped benefit.
